A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs ARC 520 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
- 28 Sep 2016 Status changed from recruiting to completed.
- 07 Jun 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
- 07 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2016.